Asset Details
Do you wish to reserve the book?
Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs
Do you wish to request the book?
Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evaluation of fluorophore-tethered platinum complexes to monitor the fate of cisplatin analogs
2015
Overview
The platinum drugs cisplatin, carboplatin, and oxaliplatin are highly utilized in the clinic and as a consequence have been extensively studied in the laboratory setting, sometimes by generating fluorophore-tagged analogs. Here, we synthesized two Pt(II) complexes containing ethane-1,2-diamine ligands linked to a BODIPY fluorophore, and compared their biological activity with previously reported Pt(II) complexes conjugated to carboxyfluorescein and carboxyfluorescein diacetate. The cytotoxicity and DNA damage capacity of Pt–fluorophore complexes was compared to cisplatin, and the Pt–BODIPY complexes were found to be more cytotoxic with reduced cytotoxicity in cisplatin-resistant cells. Microscopy revealed a predominately cytosolic localization, with nuclear distribution at higher concentrations. Spheroids grown from parent and resistant cells revealed penetration of Pt–BODIPY into spheroids, and retention of the cisplatin-resistant spheroid phenotype. While most activity profiles were retained for the Pt–BODIPY complexes, accumulation in resistant cells was only slightly affected, suggesting that some aspects of Pt–fluorophore cellular pharmacology deviate from cisplatin.
